$2.17 Billion in Sales Expected for Bausch Health Companies Inc (BHC) This Quarter

Equities analysts expect Bausch Health Companies Inc (NYSE:BHC) to post $2.17 billion in sales for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Bausch Health Companies’ earnings, with the highest sales estimate coming in at $2.20 billion and the lowest estimate coming in at $2.14 billion. Bausch Health Companies posted sales of $2.13 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 1.9%. The business is scheduled to report its next earnings results on Tuesday, August 6th.

According to Zacks, analysts expect that Bausch Health Companies will report full year sales of $8.47 billion for the current financial year, with estimates ranging from $8.42 billion to $8.53 billion. For the next financial year, analysts expect that the company will post sales of $8.78 billion, with estimates ranging from $8.51 billion to $9.30 billion. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Bausch Health Companies.

Bausch Health Companies (NYSE:BHC) last announced its earnings results on Monday, May 6th. The company reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $0.89 by $0.14. The company had revenue of $2.02 billion during the quarter, compared to the consensus estimate of $2.03 billion. Bausch Health Companies had a positive return on equity of 47.01% and a negative net margin of 19.27%. The firm’s revenue for the quarter was up 1.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.89 earnings per share.

BHC has been the subject of a number of recent analyst reports. Zacks Investment Research downgraded Bausch Health Companies from a “buy” rating to a “hold” rating in a report on Monday, January 28th. ValuEngine raised Bausch Health Companies from a “sell” rating to a “hold” rating in a research report on Monday, February 4th. Wells Fargo & Co increased their price objective on Bausch Health Companies from $9.00 to $25.19 and gave the company an “underperform” rating in a research report on Tuesday, February 19th. HC Wainwright reissued a “buy” rating on shares of Bausch Health Companies in a research report on Thursday, February 28th. Finally, Mizuho raised their price objective on Bausch Health Companies from $39.00 to $41.00 and gave the stock a “buy” rating in a research note on Monday, March 18th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and ten have assigned a buy rating to the stock. Bausch Health Companies has a consensus rating of “Hold” and an average price target of $29.13.

In other Bausch Health Companies news, CEO Joseph C. Papa acquired 30,000 shares of the company’s stock in a transaction that occurred on Thursday, February 28th. The stock was bought at an average price of $23.67 per share, for a total transaction of $710,100.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 11.87% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. FIL Ltd raised its position in Bausch Health Companies by 69.6% during the 1st quarter. FIL Ltd now owns 10,545,300 shares of the company’s stock valued at $260,170,000 after purchasing an additional 4,327,851 shares in the last quarter. Vanguard Group Inc. purchased a new stake in Bausch Health Companies in the 3rd quarter worth approximately $223,173,000. Connor Clark & Lunn Investment Management Ltd. lifted its position in Bausch Health Companies by 0.9% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 8,452,664 shares of the company’s stock worth $156,267,000 after buying an additional 75,175 shares in the last quarter. Bank of Montreal Can lifted its position in Bausch Health Companies by 28.2% in the 1st quarter. Bank of Montreal Can now owns 3,702,077 shares of the company’s stock worth $91,441,000 after buying an additional 815,311 shares in the last quarter. Finally, Orbimed Advisors LLC lifted its position in Bausch Health Companies by 89.1% in the 4th quarter. Orbimed Advisors LLC now owns 3,600,300 shares of the company’s stock worth $66,498,000 after buying an additional 1,696,400 shares in the last quarter. 54.70% of the stock is owned by institutional investors and hedge funds.

Shares of Bausch Health Companies stock traded up $0.05 during midday trading on Monday, reaching $25.33. 129,189 shares of the company’s stock traded hands, compared to its average volume of 4,289,010. The company has a quick ratio of 0.83, a current ratio of 1.08 and a debt-to-equity ratio of 8.61. The company has a market cap of $8.92 billion, a PE ratio of 6.27, a P/E/G ratio of 0.57 and a beta of 0.55. Bausch Health Companies has a 12 month low of $17.20 and a 12 month high of $28.45.

Bausch Health Companies Company Profile

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.

Read More: Balanced Fund

Get a free copy of the Zacks research report on Bausch Health Companies (BHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.